LACERO
9.6.2020 09:02:08 CEST | Business Wire | Press release
Lacero, a next generation governance technology provider for digital assets, today announced the launch of FlowOS, offering advanced transaction control and permissioning. FlowOS is now live with major cryptocurrency liquidity provider B2C2.
FlowOS enhances existing wallet and custody solutions, giving users direct, independent control of their policies, procedures and rules. A radically different solution, it is the first platform to leverage blockchain technology to create a decentralised, immutable security architecture by constructing policy from independently certified smart contracts.
Introducing real-time governance, traceability and auditability, it makes it impossible to substitute, manipulate or circumvent approved policies and procedures, and enables reliable exception-based processing with a combination of programmable rules, automated workflow procedures and human approvals.
B2C2 has selected Lacero for its best-in-class technology for governance, controls and procedures. B2C2’s integration of FlowOS, in combination with its existing integration of Fireblocks’ cutting-edge payments technology, will further enhance the firm’s settlement capabilities – the largest by some margin in the OTC markets – for the benefit of its clients.
This combination of technology platforms further demonstrates B2C2’s bank-grade security and compliance standards which, twinned with its award-winning technology and the tightest and most consistent pricing, has made it the OTC liquidity provider of choice to the largest institutional names in the industry.
B2C2’s settlement platform, enhanced by the decentralised, auditable solutions offered by Lacero and Fireblocks, is setting a market standard for straight-through-processing that is applicable to both cryptocurrency and traditional financial markets.
Rashid Hoosenally, CEO of Lacero, said: “We’re excited to be partnering with a proven industry leader who shares our vision for institutional-grade governance and controls. B2C2 strive to continuously optimise processes and tailor workflows, so we’re delighted that FlowOS has been selected to provide them with a secure, flexible enforcement platform that can support them as they grow the scale, speed and breadth of their offering.”
Max Boonen, Founder and Group CEO of B2C2, said: “B2C2’s mission to bring best practices to the trading of digital assets spans both execution and post-trade. The ability to streamline and automate both trading and settlement is the next frontier in our industry. Enhancing the B2C2 platform with Lacero’s innovative technology will allow us to better serve our clients and further scale our business as the go-to counterparty.”
Simon Heinrich, CIO and Group Head of Technology at B2C2, said: “Operational excellence and client service are at the heart of what we do at B2C2 as we are relied upon to provide institutional-grade liquidity 24/7. Given the trustless environment and irreversibility of transactions in the continuously traded and settled crypto markets, FlowOS represents a critical component of our offering as it enables controlled autonomy of our processes in a demonstrably secure way.”
-Ends-
About Lacero
Lacero develops innovative technology for governing and safeguarding digital assets and data. Its platform is underpinned by blockchain, certified smart contracts and highly secure cryptographic methods. Based in the UK, Lacero was awarded Best RegTech Policy Platform 2020
in Wealth and Finance International’s FinTech Awards. For more information on Lacero’s FlowOS platform, please visit https://www.lacero.io
About B2C2
Founded in 2015, B2C2 is the leading cryptocurrency liquidity provider. Awarded Cryptocurrency Innovation of the Year
in 2020 by FStech and Best Institutional Crypto Liquidity Provider
in 2019 by the readers of Profit & Loss, B2C2 bridges the gap between traditional financial and cryptocurrency markets. The company is trusted by brokerages, exchanges, banks and fund managers to provide 24/7 liquidity. Headquartered in the UK, with offices in London, Jersey City and Tokyo, the firm is privately held. For more information, please visit https://www.b2c2.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200609005015/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wyss Geneva Steps Into Its Next Chapter11.6.2026 13:33:00 CEST | Press release
Dr. Tracy Laabs named Director; Prof. Dr. Erwin Böttinger honored for his transformative leadership The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simult
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 13:24:00 CEST | Press release
Nearly two-thirds of patients aged 80+ treated with BRUKINSA remained progression-free at six years, despite advanced age and high-risk featuresNew European patient research reveals safety, disease severity, and effectiveness are the top drivers for first-line CLL treatment decisions – not time on therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D.,
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 13:00:00 CEST | Press release
Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib Safety profile was consistent with previous studies with no new safety signals identified Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrate
Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 13:00:00 CEST | Press release
Transaction adds 31 CLOs and more than $5 billion of AUM, strengthening Clearlake Credit’s position in liquid credit Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction
L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 12:30:00 CEST | Press release
Partnership brings together LTTS’ expertise in its Sustainability segment and the Databricks platform to accelerate Engineering Intelligence across industrial operations. L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom